MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 2 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $46.33 (43.09% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Bank of AmericaDowngradeBuy -> Neutral$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Piper JaffrayReiterated RatingPositive$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Cowen and CompanyReiterated RatingOutperform$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016AegisReiterated RatingBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Needham & Company LLCReiterated RatingBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016JMP SecuritiesReiterated RatingOutperform$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Jefferies GroupLower Price TargetBuy$50.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015Roth CapitalReiterated RatingBuy$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.27)($0.40)$0.09 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q3($0.12)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q2($0.17)($0.22)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.13)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.44)($0.44)($0.44)
Q2 20161($0.46)($0.46)($0.46)
Q3 20161($0.48)($0.48)($0.48)
Q4 20161($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)
Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateHeadline
06/29/16 02:13 PMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Company Rating and Target Watch - Telanagana Press
06/28/16 07:27 PMNotable Movers to Watch: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Emerson Electric Co. (NYSE:EMR) - NYSE Journal (press release)
06/28/16 02:16 PMMerck & Co., Inc. (NYSE:MRK) & ACADIA Pharmaceuticals (NASDAQ:ACAD) Healthcare Hot Stock's Alert - Wall Street 24
06/28/16 02:16 PMACADIA Pharmaceuticals Inc.'s Shareholders Are Having a Crazy Year. Here's Why - Motley Fool
06/28/16 12:10 PMACADIA Pharmaceuticals Inc.'s Shareholders Are Having a Crazy Year. Here's Why - Shares plunged to start the year and then came roaring back to life. Here's a recap of the major news items that have driven the company's stock in 2016.
06/27/16 02:16 PMHave a look at Analyst Actions: Merck & Company, Inc. (NYSE:MRK) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates
06/27/16 02:16 PMACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index - Business Wire (press release)
06/27/16 08:11 AMACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index - [at noodls] - SAN DIEGO--(BUSINESS WIRE)--Jun. 27, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address ...
06/27/16 07:02 AMShare Update and Earnings Review for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Press Telegraph
06/27/16 07:02 AMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Broker Price Targets For The Coming Week - Fiscal Standard
06/25/16 10:27 AMAcadia Pharmaceuticals Incorporated (NASDAQ:ACAD) Shorts Decreased by 0.68% After Short Covering - Press Telegraph
06/24/16 07:27 PMStrong Sell Calls Recommendations For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) At 0 - Investor Newswire
06/24/16 02:15 PMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 02:15 PMShare Volatility Check for: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Press Telegraph
06/24/16 10:13 AMCovering the Bases on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Where is the Stock Going? - Press Telegraph
06/22/16 07:26 PMACADIA Pharmaceuticals Inc. (ACAD) Drops 6.44% on June 21 - Equities.com
06/22/16 02:15 PMBiotechs Are Ripping Following IPAB Ruling - Benzinga
06/22/16 02:15 PMAnalyst Downgrades: McDonald's Corporation, ACADIA Pharmaceuticals Inc., and Tesla Motors Inc - Schaeffers Research (blog)
06/22/16 07:02 AMAnalyst's Noticeable Buzzers: Merck & Company, Inc. (NYSE:MRK) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates
06/21/16 02:13 PMStocks in the Spotlight: Kimco Realty Corp (NYSE:KIM), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - NYSE Journal (press release)
06/21/16 02:13 PMRecently Issued Stock Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Fiscal Standard
06/20/16 02:15 PMTop Wall Street Stories: Press Ganey (NYSE:PGND), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), ArcelorMittal ... - KC Register
06/19/16 07:01 AMThis Weeks Broker Views For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Fiscal Standard
06/18/16 07:00 AMStrong Buy Calls Count For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) At 6 - Investor Newswire
06/17/16 10:10 AMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Activities Are in the Air
06/17/16 06:16 AMLimited upside seen for Acadia Pharma -
06/16/16 07:39 PMStock under Analyst' Radar: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - News Oracle
06/16/16 02:15 PMACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016 - Business Wire (press release)
06/16/16 02:15 PMPreview of Analysts Recommendation: Astrazeneca PLC (NYSE:AZN) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates
06/16/16 09:39 AMACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016 - [at noodls] - SAN DIEGO--(BUSINESS WIRE)--Jun. 16, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address ...
06/15/16 07:02 AMHC Stocks Overview: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Athersys, Inc. (NASDAQ:ATHX) - share market updates (press release)
06/14/16 02:15 PMEarnings Overview of the Stocks: CBS Corporation (NYSE:CBS), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Beacon Chronicle
06/14/16 07:02 AMRevenue Estimates to Track: ACADIA Pharmaceuticals Inc. (ACAD) - News Oracle
06/13/16 02:15 PMAnalyst's Focused Stocks: Teva Pharmaceutical Industries (TEVA) , ACADIA Pharmaceuticals (ACAD) - Street Updates
06/13/16 02:15 PMEarnings Overview of the Stocks: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), The J. M. Smucker Company (NYSE ... - Beacon Chronicle
06/12/16 05:43 AMIs Acadia Pharmaceuticals' Stock Still a Buy? -
06/10/16 04:10 PMACADIA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
06/10/16 10:38 AMAnalyst Ratings on: Kohl's Corp. (NYSE:KSS), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Beacon Chronicle
06/10/16 10:38 AMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Rating Update - Investor Newswire
06/10/16 10:38 AMStocks inside Analysts Limelight: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) , ACADIA Pharmaceuticals Inc ... - Street Updates
06/09/16 02:13 PMAnalyst Recommended These Stocks for Investors: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Graphic ... - Beacon Chronicle
06/09/16 02:13 PMAcadia Pharmaceuticals And The Baker Brothers - Seeking Alpha
06/09/16 10:40 AMAnalysts Rating Overview: Astrazeneca PLC (NYSE:AZN) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates
06/08/16 02:16 PMAnalysts Watch-list Stocks: Galena Biopharma, Inc. (NASDAQ:GALE) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates
06/08/16 01:09 PMETF’s with exposure to ACADIA Pharmaceuticals, Inc. : June 8, 2016 -
06/08/16 10:42 AMACADIA Pharmaceuticals Inc. (ACAD) Jumps 12.78% on June 06 - Equities.com
06/08/16 10:42 AMEarnings Expectations Overview: salesforce.com, inc. (NYSE:CRM), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Beacon Chronicle
06/08/16 10:42 AMACADIA PHARMACEUTICALS INC. (NASDAQ:ACAD) Financial Condition Compared to S&P 500 - CML News
06/07/16 07:49 PMAcadia Pharmaceuticals May Be Subject Of A Bidding War - Benzinga
06/06/16 07:52 PMStocks on the Run: Vascular Biogenics Ltd (NASDAQ:VBLT), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - NYSE Journal (press release)
About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company's drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson's disease psychosis, Alzheimer's disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACAD
  • CUSIP:
Key Metrics:
  • Previous Close: $32.38
  • 50 Day Moving Average: $34.95
  • 200 Day Moving Average: $28.43
  • P/E Ratio: N/A
  • P/E Growth: -0.27
  • Market Cap: $3.66B
  • Current Quarter EPS Consensus Estimate: $-1.70 EPS
Additional Links:
ACADIA Pharmaceuticals (NASDAQ:ACAD) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha